HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

James G Krueger Selected Research

efalizumab

1/2012Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.
11/2008Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.
5/2008Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
1/2007Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
12/2005Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).
3/2005Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.
1/2005Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
10/2004Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
5/2002Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


James G Krueger Research Topics

Disease

76Psoriasis (Pustulosis Palmaris et Plantaris)
11/2015 - 05/2002
17Inflammation
01/2015 - 07/2004
15Atopic Dermatitis (Atopic Eczema)
11/2015 - 11/2008
8Hyperplasia
11/2015 - 04/2006
8Neoplasms (Cancer)
09/2014 - 04/2006
7Skin Diseases
11/2015 - 02/2005
4Autoimmune Diseases (Autoimmune Disease)
03/2008 - 10/2004
2Alopecia Areata
11/2015 - 01/2015
2Contact Dermatitis (Eczema, Contact)
03/2015 - 08/2014
2Hypersensitivity (Allergy)
01/2015 - 10/2014
2Melanoma (Melanoma, Malignant)
01/2015 - 12/2013
2Cardiovascular Diseases (Cardiovascular Disease)
08/2013 - 07/2010
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2013 - 01/2011
2Rheumatoid Arthritis
01/2010 - 05/2007
1Parakeratosis
11/2015
1Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
09/2015
1Joint Diseases (Joint Disease)
04/2015
1Allergic Contact Dermatitis
03/2015
1Neoplasm Metastasis (Metastasis)
01/2015
1Warts (Wart)
01/2015
1Atherosclerosis
01/2015
1Mycosis Fungoides
09/2014
1Disease Progression
09/2014
1Basal Cell Carcinoma (Rodent Ulcer)
12/2013
1Arthritis (Polyarthritis)
08/2013
1Lyme Disease (Disease, Lyme)
05/2013
1Necrosis
03/2013
1Actinic Keratosis
02/2013
1Starvation
01/2013
1Chronic Disease (Chronic Diseases)
12/2012
1Acute Disease
12/2012

Drug/Important Bio-Agent (IBA)

19Interleukin-17 (Interleukin 27)IBA
04/2015 - 05/2008
19CytokinesIBA
01/2015 - 07/2004
16Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2015 - 07/2004
12Interleukin-23 (Interleukin 23)IBA
11/2015 - 01/2004
9Messenger RNA (mRNA)IBA
08/2015 - 02/2003
9efalizumabFDA Link
01/2012 - 05/2002
8Interleukin-12 (IL 12)IBA
01/2012 - 02/2003
6TNFR-Fc fusion protein (etanercept)FDA Link
02/2011 - 08/2005
5ChemokinesIBA
01/2015 - 07/2004
5InterleukinsIBA
04/2013 - 01/2004
5interleukin-22 (IL-22)IBA
01/2013 - 11/2008
5Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
10/2010 - 12/2005
5alefacept (Amevive)FDA Link
01/2010 - 02/2005
3Biological Markers (Surrogate Marker)IBA
11/2015 - 06/2007
3Proteins (Proteins, Gene)IBA
11/2014 - 06/2011
3Cyclosporine (Ciclosporin)FDA LinkGeneric
10/2014 - 02/2008
3Interleukin-8 (Interleukin 8)IBA
12/2013 - 08/2005
3Keratin-16 (Keratin 16)IBA
01/2013 - 05/2002
3adjuvant P40 (P 40)IBA
08/2011 - 01/2004
2AntigensIBA
10/2015 - 09/2011
2Methotrexate (Mexate)FDA LinkGeneric
08/2015 - 06/2004
2RNA (Ribonucleic Acid)IBA
05/2015 - 01/2012
2Toll-Like Receptors (Toll-Like Receptor)IBA
01/2015 - 01/2013
2Interleukin-10 (Interleukin 10)IBA
01/2015 - 10/2007
2diphenylcyclopropenoneIBA
01/2015 - 10/2014
2Monoclonal AntibodiesIBA
01/2015 - 08/2011
2Interleukin-1 (Interleukin 1)IBA
04/2013 - 08/2005
2TNF-Related Apoptosis-Inducing LigandIBA
03/2013 - 06/2010
2PeptidesIBA
07/2012 - 06/2009
2AntibodiesIBA
06/2011 - 03/2008
2interleukin 20 (IL-20)IBA
06/2011 - 07/2006
2HLA-DR Antigens (HLA-DR)IBA
10/2010 - 10/2009
2infliximab (Remicade)FDA Link
03/2008 - 05/2007
2InterferonsIBA
10/2007 - 01/2004
1Immunoglobulin E (IgE)IBA
11/2015
1aurora kinase (aurora A kinase)IBA
09/2015
1adalimumab (Humira)FDA Link
08/2015
1P-2 (P 2)IBA
07/2015
1AllergensIBA
03/2015
1MicroRNAs (MicroRNA)IBA
03/2015
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2015
1E-SelectinIBA
01/2015
1Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
01/2015
1DinitrofluorobenzeneIBA
08/2014
1NickelIBA
08/2014
1Blood Proteins (Serum Proteins)IBA
01/2014
1MitogensIBA
12/2013
1anaplastic lymphoma kinaseIBA
12/2013
1apremilastIBA
08/2013
1Erythema migransIBA
05/2013
1Biological Tumor Markers (Tumor Markers)IBA
03/2013
1interleukin-22 receptor (IL-22R)IBA
01/2013
1harpin (messenger)IBA
01/2013
1tebufenozide (Mimic)IBA
01/2013
1Toll-Like Receptor 7IBA
01/2013
1Complementary DNA (cDNA)IBA
06/2012
1omega-Chloroacetophenone (Mace)IBA
08/2011
13- (2- carboxypiperazin- 4- yl)propyl- 1- phosphonic acid (CPP)IBA
08/2011
1briakinumabIBA
08/2011
1monoclonal antibody CNTO 1275 (CNTO 1275)FDA Link
08/2011

Therapy/Procedure

9Therapeutics
11/2015 - 02/2003
5Lasers (Laser)
03/2015 - 01/2011
4Biological Therapy
08/2011 - 01/2005
2Individualized Medicine
11/2015 - 01/2010
2Transplants (Transplant)
01/2013 - 06/2007
2Intradermal Injections
01/2013 - 04/2012
2Immunotherapy
06/2012 - 02/2005
1Oral Administration
01/2012
1Phototherapy (Light Therapy)
09/2011